| Document |
Document Title |
|
WO/2024/067796A1 |
Provided are a non-human animal expressing a human or chimeric (e.g. humanized) IL5 and/or IL5RA protein, and a use method therefor.
|
|
WO/2024/071368A1 |
The present invention provides an adjuvant and a transmucosal vaccine that are highly capable of inducing secretory IgA in addition to serum IgA and IgG when transmucosally administered. The invention relates to the adjuvant that compr...
|
|
WO/2024/073583A1 |
The invention comprises anti-ROR1 chimeric antigen receptor (CAR) T cells (CAR-T cells) natural killer cells (CAR-NK cells), compositions comprising the cells and methods of making and using the same, including methods of treatment of RO...
|
|
WO/2024/069176A1 |
The present invention relates to clostridial neurotoxins engineered to comprise an exogenous protease cleavage site within a modified activation loop, wherein cleavage at said site produces an active di-chain clostridial neurotoxin. The ...
|
|
WO/2024/066941A1 |
Provided is a composition for detecting bladder cancer. The composition comprises a detection reagent for detecting at least one of the following methylation sites: cg00206063, cg03278514, and cg13314394. Also provided are use of the com...
|
|
WO/2024/073440A1 |
Provided herein, inter alia, are methods and compositions for engineering T cells. The methods include contacting a T cell with a nucleic acid and one or more cyclic GMP- AMP synthase (cGAS) - stimulator of interferon gene (STING) pathwa...
|
|
WO/2024/073397A1 |
This invention relates synthetic tetraspanin proteins comprising a heterologous protein or fragment thereof inserted within the second extracellular loop of a tetraspanin backbone, wherein the heterologous protein or fragment thereof is ...
|
|
WO/2023/150696A9 |
Provided is a recombinant milk protein for delivery of a hydrophobic bioactive agent, a composition comprising such recombinant milk protein, and a method for using such composition.
|
|
WO/2024/071401A1 |
The present inventors found that enhancement of Plk1 activity induces lethal chromosome dynamic abnormalities in cancer cells and inhibits the proliferation thereof. Thus, activation of Plk1 and exacerbation of chromosome instability can...
|
|
WO/2024/067785A1 |
Provided is use for the treatment of chronic hepatitis B based on an interferon synergistic immune checkpoint blocking antibody. Specifically, provided is a fusion protein, comprising a PDL1-binding polypeptide and an interferon IFN whic...
|
|
WO/2024/072224A2 |
The present invention relates to a peptide-based compound for complexing and stabilizing a double stranded oligonucleotide, the compound comprising a structure p-x-b-x'-p'; wherein: i. p and p' each refer to an oligonucleotide-binding mo...
|
|
WO/2024/073043A1 |
Provided herein are methods, compositions, and kits related to using a CpG binding protein. In one embodiment, the present disclosure includes methods, compositions, and kits related to using a CpG binding protein with a cytidine deamina...
|
|
WO/2024/069240A2 |
Provided herein are methods of treating cancer (e.g., CD38-expressing cancer such as multiple myeloma) using a CD38-binding fusion protein comprising an anti-CD38 antibody fused to one or more attenuated interferon alpha-2b protein in co...
|
|
WO/2024/065882A1 |
An amino acid-based multifunctional water-based liquid, a preparation method therefor and a use thereof. In the water-based liquid, water is used as a solvent, and viscous droplets rich in amino acids, oligopeptides or/and amino acid/oli...
|
|
WO/2024/069527A1 |
Phage for the specific capture of the SARS-CoV-2 virus, said phage being an M13 phage engineered to display on the P8 protein of its coat either FHKGGYEKTWKLGD sequence peptides or EFTSKAR sequence peptides, said peptides having speci fi...
|
|
WO/2024/069010A1 |
Subject matter of the present invention is a delivery vector comprising a DNA sequence encoding pre-prodynorphin or pre-prodynorphin-variants and wherein said delivery vector drives expression of a pre- propeptide in a target cell, and w...
|
|
WO/2024/071964A1 |
The present invention relates to: a fusion polypeptide in which a His tag is fused with a peptide tag having main amino acids composed of charged and polar amino acids; a fusion protein in which the fusion polypeptide is fused with a tar...
|
|
WO/2024/071362A1 |
The present invention addresses the problem of providing a new method for improving the delivery efficiency of a drug such as a nucleic acid drug to the nervous system. Provided is a delivery enhancer for enhancing the delivery of a dr...
|
|
WO/2024/071957A1 |
The present invention relates to an amorphous peptide tag with main amino acids composed of charged and hydrophobic amino acids, a fusion protein in which the tag is fused with a target protein, and a method for purifying the target prot...
|
|
WO/2024/072985A1 |
Disclosed are methods of treating and/or inhibiting an intramammary infection in a mammalian subject. The methods included administering a therapeutically effective amount of surface-associated polypeptides from various bacteria. Also di...
|
|
WO/2024/069549A1 |
The present disclosure relates generally to vaccine constructs comprising a polynucleotide encoding a salmon alphavirus-like particle and uses thereof, including for inducing an immune response against salmonid alphavirus.
|
|
WO/2024/071970A1 |
The present invention relates to: a fusion polypeptide comprising a His tag, and a peptide tag of which the main amino acids are charged amino acids; a fusion protein in which the fusion polypeptide and a target protein are fused; and a ...
|
|
WO/2024/068827A1 |
The invention relates to a method for manufacturing a precipitated mixture, which contains liraglutide or a salt thereof (component (A)), comprising the steps of removing solid parts, mixing with an antisolvent, stirring precipitation su...
|
|
WO/2024/067153A1 |
Provided are a nucleic acid for producing rAAV in an insect cell, a VP1 capsid protein mutant, and use. The nucleic acid comprises nucleotide sequences encoding adeno-associated viruses VP1, VP2, and VP3 proteins. Compared with the capsi...
|
|
WO/2024/073606A1 |
Methods for improving engraftment of donor cells in a subject thereof are provided. Such methods can comprise providing donor cells that have been modified to express a first isoform of a target protein (e.g., interleukin-2 receptor subu...
|
|
WO/2024/067723A1 |
A respiratory syncytial virus subtype A (RSV-A) recombinant F protein, a polynucleotide, a nucleic acid construct, an expression vector, a host cell, a stabilized trimer formed by the recombinant F protein, an immunogenic composition com...
|
|
WO/2024/068617A1 |
The present invention concerns a modified cell comprising a transgene coding for interleukin-2 (IL-2). Said modified cell comprises a first vector comprising a sequence coding for IL-2 under the control of an inducible or constitutive pr...
|
|
WO/2024/073697A1 |
The disclosure relates to Respiratory Syncytial Virus (RSV) vaccine compositions having truncated mucin domains in the G-protein. In certain embodiments, this disclosure relates to virus particles, virus-like particles, virosomes, nuclei...
|
|
WO/2024/072958A1 |
The present invention relates to engineering synthetic major histocompatibility complex (MHC) molecules for generating universal peptide/MHC complexes with engineered disulfide linkage(s) using structure-guided modeling and design and me...
|
|
WO/2024/072954A1 |
A method to oxidize pan-cancer epitopes of COL6A3 protein (peptide sequences 1. FLLDGSANV (SEQ ID NO: 1), 2. FLLDGSEGV (SEQ ID NO: 2) and 3. FLLDGSINF (SEQ ID NO: 3)) by cold atmospheric plasma treatment for developing solid tumor cancer...
|
|
WO/2024/071043A1 |
Provided is a novel production method of a hetero that enables the production of a heteromultimeric protein such as a bispecific antibody. The production method of the present disclosure, which is for producing a heteromultimeric prote...
|
|
WO/2024/062417A1 |
The present disclosure relates to enzymes, compositions and methods for performing conditional homologous recombination of a targeted DNA molecule or genome by using modified proteins comprising nucleic acid DNA binding proteins with pro...
|
|
WO/2024/064446A2 |
Disclosed herein are compositions comprising a recombinant polypeptide targeting phosphatidylserine on the surface of cancer cells and methods of using the compositions to treat a cancer in a subject.
|
|
WO/2024/064744A2 |
Engineered split dihydrofolate reductase-based methods and systems are provided for selecting cells that have stably acquired a heterologous polynucleotide.
|
|
WO/2024/064782A2 |
Provided herein are recombinant adeno-associated virus (AAV) capsid proteins, compositions (e.g., rAAV) comprising the capsid proteins, nucleic acids encoding the capsid proteins, and methods of making and using the capsid proteins.
|
|
WO/2024/062149A1 |
The present invention relates to compounds, especially to conjugates and derivatives of alternariol labelled at specific positions in the molecule, suitable for the production of antibodies with a high affinity for alternariol. Likewise,...
|
|
WO/2024/061753A1 |
The present invention relates to trimeric class I fusion proteins, in particular to class I fusion proteins, comprising at least one stabilizing mutation in the HR2 domain, and to fragments thereof.
|
|
WO/2024/064860A1 |
Disclosed herein are non-human animals (e.g., rodents, e.g., mice or rats) genetically engineered to express a humanized or human T cell receptor (TCR) comprising a variable domain encoded by (a) at least one human TCR variable region γ...
|
|
WO/2024/064653A1 |
Provided herein, inter alia, are variant lectin anti-viral polypeptides as well as compositions and methods for expressing and using the same for the treatment and prevention of viral disease in animals.
|
|
WO/2024/064612A1 |
The present application concerns selected engineered analogs of atrial natriuretic peptides, compositions that contain these peptides and uses thereof to treat, prevent, or alleviate the symptoms of cardiovascular, cardiorenal, or metabo...
|
|
WO/2024/064640A2 |
Disclosed herein are chimeric antigen receptors (CARs) comprising an antigen binding site that recognizes citrullinated polypeptides. Citru llinated polypeptides, such as citrullinated vimentin, are expressed in the skin lesions of subje...
|
|
WO/2024/062098A1 |
The present invention relates to the field of viral immunotherapy. In particular, the invention concerns a novel recombinant pseudocowpox virus (PCPV) comprising a nucleic acid molecule inserted in its genome and encoding an interleukine...
|
|
WO/2024/064863A2 |
Provided herein are gene therapy compositions and methods of treating loss of cardiomyocyte alignment due to reduced levels of functional plakophilin-2 protein in a subject having arrhythmogenic cardiomyopathy. Also provided herein are g...
|
|
WO/2024/063611A2 |
The present invention relates to a hydroxy fatty acid and a hydroxy fatty acid derivative derived from long-chain fatty acids and functioning as agonists for fatty acid receptors such as GPR40 and GPR120. The hydroxy fatty acid and the h...
|
|
WO/2024/064856A1 |
Provided herein are gene therapy compositions and methods of treating reduced levels of functional cardiac myosin binding protein C in a subject having hypertrophic cardiomyopathy.
|
|
WO/2024/061239A1 |
Provided are a fusion protein for preventing or treating coronavirus infection, a Spike protein nanoparticle, and a preparation thereof. The fusion protein comprises a mutation-containing coronavirus Spike protein extracellular domain wh...
|
|
WO/2024/064802A2 |
Described and featured are immunogenic compositions comprising non-naturally occurring pan-fungal kexin peptides and methods of using such compositions for the treatment or prevention of various diseases or severe diseases, and/or the sy...
|
|
WO/2024/064763A2 |
Variants of coagulation factor VIII (FVIII) and expression cassettes encoding the FVIII variants thereof are described. A variant FVIII includes a glycoepitope of the FVIII protein including an N2118Q mutation. The N2118Q mutation can be...
|
|
WO/2024/064931A1 |
The present disclosure provides compositions (e.g., pharmaceutical compositions) for delivery of Plasmodium protein antigens and related technologies (e.g., components thereof and/or methods relating thereto). Among other things, the pre...
|
|
WO/2024/064913A1 |
The present disclosure provides gene therapy vectors, such as recombinant adeno-associated virus (rAAV) for expressing a human micro-dystrophin gene. The present disclosure also provides compositions and methods of using these rAAV to tr...
|
